Cargando…

Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants

Polypharmacy is common in patients with atrial fibrillation (AF), making these patients vulnerable to the occurrence of potential drug-drug interactions (DDIs). We assessed the risk of ischemic stroke and major bleeding in the context of concomitant treatment with potential DDIs in patients with AF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Yun, Oh, Il-Young, Lee, Ju-Hyeon, Kim, Seok, Cho, Jihoon, Park, Charg Hyun, Yoo, Sooyoung, Bang, Soo-Mee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599657/ https://www.ncbi.nlm.nih.gov/pubmed/34789799 http://dx.doi.org/10.1038/s41598-021-01786-2

Ejemplares similares

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2018)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Reduction of major gastrointestinal bleeding risk with proton pump inhibitor therapy in patients with atrial fibrillation receiving direct oral anticoagulant
por: Lee, S R, et al.
Publicado: (2023)

Patients and Their Physician’s Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant
por: Cannon, Christopher P., et al.
Publicado: (2023)

The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2020)

Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies
por: Bang, Oh Young, et al.
Publicado: (2023)

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
por: Briasoulis, Alexandros, et al.
Publicado: (2020)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation
por: Villain, Cédric, et al.
Publicado: (2023)

Novel Drug Interaction index and Risk of Mortality in Older Patients With Atrial Fibrillation Receiving Non Vitamin K Oral Anticoagulants (NOEL Drug)
por: Ersoy, İbrahim
Publicado: (2021)

Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation
por: Lee, Kwang-No, et al.
Publicado: (2019)

Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants
por: Baker, Christine L., et al.
Publicado: (2019)

Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation
por: Park, Jiesuck, et al.
Publicado: (2019)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)

Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation
por: Giustozzi, Michela, et al.
Publicado: (2020)

Impact of drug interactions with direct oral anticoagulants on mortality in elderly with atrial fibrillation during the COVID-19 pandemic
por: Ersoy, İbrahim, et al.
Publicado: (2023)

Impact of drug interactions with direct oral anticoagulants on mortality in elderly with atrial fibrillation during the COVID-19 pandemic
por: Ersoy, İbrahim, et al.
Publicado: (2023)

The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
por: Zheng, Huan Jie, et al.
Publicado: (2017)

Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Renal Impairment
por: Jang, Soo Min, et al.
Publicado: (2020)

Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
por: Yamato, Hiroshi, et al.
Publicado: (2020)

Association of Gender With Clinical Outcomes in a Contemporary Cohort of Patients With Atrial Fibrillation Receiving Oral Anticoagulants
por: Kim, Minjeong, et al.
Publicado: (2022)

Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
por: Prídavková, Dana, et al.
Publicado: (2019)

Direct Oral Anticoagulants in Old and Frail Patients with Atrial Fibrillation: The Advantages of an Anticoagulation Service
por: Vedovati, Maria Cristina, et al.
Publicado: (2022)

Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies
por: Mueller, Tanja, et al.
Publicado: (2017)

Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
por: Baker, Christine L., et al.
Publicado: (2018)

Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Relationship between the degree of renal dysfunction and the safety and efficacy outcomes in patients with atrial fibrillation receiving direct oral anticoagulants
por: Wada, Ryo, et al.
Publicado: (2021)

Infarct Volumes of Patients with Acute Ischemic Stroke Receiving Direct Oral Anticoagulants due to Non-Valvular Atrial Fibrillation
por: Yavasoglu, Nese G., et al.
Publicado: (2021)

Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
por: Botto, Gianluca, et al.
Publicado: (2021)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
por: Lee, Kwang-No, et al.
Publicado: (2020)

Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2020)

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy
por: Søgaard, Mette, et al.
Publicado: (2022)

Incidence of Osteoporosis in Primary Care Patients with Atrial Fibrillation Receiving Different Oral Anticoagulants
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2022)

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014)

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion
por: Coppola, Giuseppe, et al.
Publicado: (2019)

Convenience and satisfaction in direct oral anticoagulant–treated patients with atrial fibrillation
por: Piersma‐Wichers, Margriet, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_16icc49e0s4odbchi728ep74ig